swi fallback featured image 1 - Belgian News
Last Updated: September 30, 2025Views: 690.3 min read

(Bloomberg) — Shares in Belgium’s UCB SA soared to a record, while rival MoonLake Immunotherapeutics is set to lose most of its value, after the latter announced late-stage trial data for an experimental skin disease drug that analysts said failed to demonstrate superiority to one of UCB’s most important medicines.
Read full article

Leave A Comment